{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:29:08Z","timestamp":1786980548023,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10147-026-02959-7","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T11:19:13Z","timestamp":1768648753000},"page":"467-475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of bevacizumab-combined single-agent chemotherapy for platinum-resistant ovarian cancer that recurred during PARP inhibitor treatment"],"prefix":"10.1007","volume":"31","author":[{"given":"Eriko","family":"Takatori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9022-3333","authenticated-orcid":false,"given":"Tadahiro","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miku","family":"Musashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Tatsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanako","family":"Jonai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Kaido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Nagasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kagabu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Aida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"key":"2959_CR1","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1002\/ijc.34002","volume":"151","author":"CJ Cabasag","year":"2022","unstructured":"Cabasag CJ, Fagan PJ, Ferlay J et al (2022) Ovarian cancer today and tomorrow: a global assessment by world region and Human Development Index using GLOBOCAN 2020. Int J Cancer 151:1535\u20131541. https:\/\/doi.org\/10.1002\/ijc.34002","journal-title":"Int J Cancer"},{"key":"2959_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"key":"2959_CR3","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194\u20133200","journal-title":"J Clin Oncol"},{"key":"2959_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","volume":"41","author":"P DiSilvestro","year":"2023","unstructured":"DiSilvestro P, Banerjee S, Colombo N et al (2023) Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial. J Clin Oncol 41:609\u2013617. https:\/\/doi.org\/10.1200\/JCO.22.01549","journal-title":"J Clin Oncol"},{"key":"2959_CR5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","volume":"34","author":"I Ray-Coquard","year":"2023","unstructured":"Ray-Coquard I, Leary A, Pignata S et al (2023) Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. Ann Oncol 34:681\u2013692. https:\/\/doi.org\/10.1016\/j.annonc.2023.05.005","journal-title":"Ann Oncol"},{"key":"2959_CR6","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I et al (2019) Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 381:2391\u20132402. https:\/\/doi.org\/10.1056\/NEJMoa1910962","journal-title":"N Engl J Med"},{"key":"2959_CR7","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1001\/jamaoncol.2023.2283","volume":"9","author":"N Li","year":"2023","unstructured":"Li N, Zhu J, Yin R et al (2023) Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial. JAMA Oncol 9:1230\u20131237. https:\/\/doi.org\/10.1001\/jamaoncol.2023.2283","journal-title":"JAMA Oncol"},{"key":"2959_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ygyno.2019.10.023","volume":"156","author":"SC Cecere","year":"2020","unstructured":"Cecere SC, Giannone G, Salutari V et al (2020) Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: real world data and post progression outcome. Gynecol Oncol 156:38\u201344. https:\/\/doi.org\/10.1016\/j.ygyno.2019.10.023","journal-title":"Gynecol Oncol"},{"key":"2959_CR9","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1097\/CAD.0000000000001219","volume":"32","author":"PG Rose","year":"2021","unstructured":"Rose PG, Yao M, Chambers LM et al (2021) PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer. Anticancer Drugs 32:1086\u20131092. https:\/\/doi.org\/10.1097\/CAD.0000000000001219","journal-title":"Anticancer Drugs"},{"key":"2959_CR10","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.21873\/anticanres.15681","volume":"42","author":"A Gadducci","year":"2022","unstructured":"Gadducci A, Cosio S, Landoni F et al (2022) Response to chemotherapy and clinical outcome of patients with recurrent epithelial ovarian cancer after PARP inhibitor maintenance treatment: a multicenter retrospective Italian study. Anticancer Res 42:2017\u20132022. https:\/\/doi.org\/10.21873\/anticanres.15681","journal-title":"Anticancer Res"},{"key":"2959_CR11","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.21873\/anticanres.16273","volume":"43","author":"M Abe","year":"2023","unstructured":"Abe M, Shoji T, Chiba Y et al (2023) Efficacy and safety of platinum-based chemotherapy with bevacizumab followed by bevacizumab maintenance for recurrent ovarian, fallopian tube, and primary peritoneal cancer during PARP inhibitor therapy: a multicenter retrospective study. Anticancer Res 43:1265\u20131272. https:\/\/doi.org\/10.21873\/anticanres.16273","journal-title":"Anticancer Res"},{"key":"2959_CR12","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1186\/s12885-018-4505-4","volume":"18","author":"T Shoji","year":"2018","unstructured":"Shoji T, Komiyama S, Kigawa J et al (2018) An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023. BMC Cancer 18:771. https:\/\/doi.org\/10.1186\/s12885-018-4505-4","journal-title":"BMC Cancer"},{"key":"2959_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"2959_CR14","unstructured":"Common Toxicity Criteria for Adverse Events version 5.0 (CTCAE). Available at: Common Terminology Criteria for Adverse Events (CTCAE). https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf (Last accessed 23 Feb 2025)"},{"key":"2959_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48:452\u2013458","journal-title":"Bone Marrow Transplant"},{"key":"2959_CR16","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B et al (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 32:1302\u20131308. https:\/\/doi.org\/10.1200\/JCO.2013.51.4489","journal-title":"J Clin Oncol"},{"key":"2959_CR17","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/cas.15185","volume":"113","author":"T Shoji","year":"2022","unstructured":"Shoji T, Enomoto T, Abe M et al (2022) Efficacy and safety of standard of care with\/without bevacizumab for platinum-resistant ovarian\/fallopian tube\/peritoneal cancer previously treated with bevacizumab: the Japanese Gynecologic Oncology Group study JGOG3023. Cancer Sci 113:240\u2013250. https:\/\/doi.org\/10.1111\/cas.15185","journal-title":"Cancer Sci"},{"key":"2959_CR18","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","volume":"25","author":"DG Mutch","year":"2007","unstructured":"Mutch DG, Orlando M, Goss T et al (2007) Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25:2811\u20132818","journal-title":"J Clin Oncol"},{"key":"2959_CR19","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1200\/JCO.2011.38.8082","volume":"30","author":"N Colombo","year":"2012","unstructured":"Colombo N, Kutarska E, Dimopoulos M et al (2012) Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol 30:3841\u20133847. https:\/\/doi.org\/10.1200\/JCO.2011.38.8082","journal-title":"J Clin Oncol"},{"key":"2959_CR20","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2025.36.e36","volume":"36","author":"L Zhong","year":"2025","unstructured":"Zhong L, Wang H, Lei C et al (2025) Bevacizumab combined with chemotherapy could be superior to chemotherapy alone in relapsed ovarian cancer after PARPi: evidence from a multi-center propensity score-matched analysis. Gynecol Oncol 36:e36. https:\/\/doi.org\/10.3802\/jgo.2025.36.e36","journal-title":"Gynecol Oncol"},{"key":"2959_CR21","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.21873\/anticanres.15964","volume":"42","author":"S Tatsuki","year":"2022","unstructured":"Tatsuki S, Shoji T, Abe M et al (2022) Efficacy and safety of platinum rechallenge in patients with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: a multicenter retrospective study. Anticancer Res 42:4603\u20134610. https:\/\/doi.org\/10.21873\/anticanres.15964","journal-title":"Anticancer Res"},{"key":"2959_CR22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ygyno.2018.05.020","volume":"150","author":"K Lindemann","year":"2018","unstructured":"Lindemann K, Gao B, Mapagu C et al (2018) Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. Gynecol Oncol 150:239\u2013246. https:\/\/doi.org\/10.1016\/j.ygyno.2018.05.020","journal-title":"Gynecol Oncol"},{"key":"2959_CR23","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.21037\/tcr-2025-641","volume":"14","author":"Q Wang","year":"2025","unstructured":"Wang Q, Kuang L, Liu B et al (2025) A real-world retrospective cohort study: the clinical outcomes and characteristics of platinum-resistant recurrent ovarian cancer. Transl Cancer Res 14:3161\u20133174. https:\/\/doi.org\/10.21037\/tcr-2025-641","journal-title":"Transl Cancer Res"},{"key":"2959_CR24","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.21873\/anticanres.17910","volume":"45","author":"E Takatori","year":"2025","unstructured":"Takatori E, Shoji T, Jo A et al (2025) Efficacy of platinum-based chemotherapy for platinum-sensitive recurrent ovarian cancer during PARP inhibitor treatment: a multicenter retrospective study. Anticancer Res 45:5773\u20135783. https:\/\/doi.org\/10.21873\/anticanres.17910","journal-title":"Anticancer Res"},{"key":"2959_CR25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ygyno.2023.03.007","volume":"172","author":"C Valenza","year":"2023","unstructured":"Valenza C, Cardellino GG, Spadola S et al (2023) Reversion mutations in BRCA genes in high-grade serous ovarian cancer: implications for platinum and PARP inhibitor resistance. Gynecol Oncol 172:403\u2013410. https:\/\/doi.org\/10.1016\/j.ygyno.2023.03.007","journal-title":"Gynecol Oncol"},{"key":"2959_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12943-025-02355-1","volume":"24","author":"Y Zou","year":"2025","unstructured":"Zou Y, Li Z, Zhu Y et al (2025) PARP inhibitor resistance in ovarian cancer: mechanisms and therapeutic strategies. Mol Cancer 24:55. https:\/\/doi.org\/10.1186\/s12943-025-02355-1","journal-title":"Mol Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-02959-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-02959-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-02959-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:03:22Z","timestamp":1771952602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-02959-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2959"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-02959-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7904976\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors of this manuscript have any conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}